新华鲜报丨超100种！我国医保罕见病用药创新高

Group 1 - The new national medical insurance drug list includes over 100 rare disease medications, covering more than 50 disease types, providing hope for more patients [2] - The drug Lenvatinib, approved for Langerhans cell histiocytosis, has a high monthly treatment cost of approximately 17,000 yuan, making it unaffordable for many patients [2] - The inclusion of Lenvatinib in the insurance list allows treatment for both Langerhans cell histiocytosis and neurofibromatosis type I in children aged 2 and above, expanding access compared to previous medications [4] Group 2 - The national medical insurance has covered over 50 rare disease types, but there remains a gap compared to the 207 rare diseases listed, due to high costs and lack of available treatments [4] - The introduction of commercial insurance for innovative drugs includes 19 medications, including Lenvatinib, allowing for discounted pricing and reducing the financial burden on families [7] - Initiatives such as the publication of clinical guidelines for 86 rare diseases and the establishment of a national rare disease diagnosis and treatment network are enhancing support for patients [7]